Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Contieri

Showing results (101-110 of 138) with videos related to

Pageof 14
Sort By:
Current Oncology (Toronto, Ont.)|June 25, 2026
Real-World Analysis of Metastatic Renal Cell Carcinoma Patients Treated with Pembrolizumab Plus Axitinib: Evidence from the Campania Oncology NetworkMarilena Di Napoli, Elisabetta Coppola, Carmine D'Aniello, et al.
BJU International|March 13, 2026
Risk stratification and conditional recurrence after radical cystectomy: toward adaptive follow-upRoberto Contieri, Alberto Martini, Marc Furrer, et al.
European Urology Oncology|June 21, 2024
Consistencies in Follow-up After Radical Cystectomy for Bladder Cancer: A Framework Based on Expert Practices Collaboratively Developed by the European Association of Urology Bladder Cancer Guideline PanelsLaura S Mertens, Harman Maxim Bruins, Roberto Contieri, et al.
BJU International|March 20, 2026
Refining BCG-failure classifications in non-muscle-invasive bladder cancerAleksander Ślusarczyk, Pietro Scilipoti, Roberto Contieri, et al.
Urologic Oncology|June 8, 2022
Predictive clinico-pathological factors to identify BCG, unresponsive patients, after re-resection for T1 high grade non-muscle invasive bladder cancerMatteo Ferro, Biagio Barone, Felice Crocetto, et al.
Cancers|July 12, 2025
Prognostic Impact of Adjuvant Immunotherapy in Patients with High-Risk Upper Tract Urothelial Cancer: Results from the ROBUUST 2.0 Collaborative GroupMaxwell Otiato, Farshad Sheybaee Moghaddam, Alireza Ghoreifi, et al.
Diagnostics (Basel, Switzerland)|March 25, 2022
Modified Glasgow Prognostic Score as a Predictor of Recurrence in Patients with High Grade Non-Muscle Invasive Bladder Cancer Undergoing Intravesical Bacillus Calmette-Guerin ImmunotherapyMatteo Ferro, Octavian Sabin Tătaru, Gennaro Musi, et al.
BJU International|February 26, 2026
Impact of BCG failure patterns on efficacy of intravesical gemcitabine/docetaxel in high-risk non-muscle-invasive bladder cancerPietro Scilipoti, Paolo Zaurito, Mattia Longoni, et al.
Annals of Surgical Oncology|March 21, 2026
Bladder Tumor Location Matters: Trigone and Bladder Neck Involvement Predict Worse Oncological Outcomes in High-Grade Non-Muscle-Invasive Bladder CancerAleksander Ślusarczyk, Marco Moschini, Wojciech Krajewski, et al.
Urologic Oncology|February 26, 2022
Variant histologies in bladder cancer: Does the centre have an impact in detection accuracy?Alessia Cimadamore, Chiara Lonati, Ettore Di Trapani, et al.
Pageof 14

Showing results (101-110 of 138) with videos related to

Sort By:
Pageof 14
Current Oncology (Toronto, Ont.)|June 25, 2026
Real-World Analysis of Metastatic Renal Cell Carcinoma Patients Treated with Pembrolizumab Plus Axitinib: Evidence from the Campania Oncology NetworkMarilena Di Napoli, Elisabetta Coppola, Carmine D'Aniello, et al.
BJU International|March 13, 2026
Risk stratification and conditional recurrence after radical cystectomy: toward adaptive follow-upRoberto Contieri, Alberto Martini, Marc Furrer, et al.
European Urology Oncology|June 21, 2024
Consistencies in Follow-up After Radical Cystectomy for Bladder Cancer: A Framework Based on Expert Practices Collaboratively Developed by the European Association of Urology Bladder Cancer Guideline PanelsLaura S Mertens, Harman Maxim Bruins, Roberto Contieri, et al.
BJU International|March 20, 2026
Refining BCG-failure classifications in non-muscle-invasive bladder cancerAleksander Ślusarczyk, Pietro Scilipoti, Roberto Contieri, et al.
Urologic Oncology|June 8, 2022
Predictive clinico-pathological factors to identify BCG, unresponsive patients, after re-resection for T1 high grade non-muscle invasive bladder cancerMatteo Ferro, Biagio Barone, Felice Crocetto, et al.
Cancers|July 12, 2025
Prognostic Impact of Adjuvant Immunotherapy in Patients with High-Risk Upper Tract Urothelial Cancer: Results from the ROBUUST 2.0 Collaborative GroupMaxwell Otiato, Farshad Sheybaee Moghaddam, Alireza Ghoreifi, et al.
Diagnostics (Basel, Switzerland)|March 25, 2022
Modified Glasgow Prognostic Score as a Predictor of Recurrence in Patients with High Grade Non-Muscle Invasive Bladder Cancer Undergoing Intravesical Bacillus Calmette-Guerin ImmunotherapyMatteo Ferro, Octavian Sabin Tătaru, Gennaro Musi, et al.
BJU International|February 26, 2026
Impact of BCG failure patterns on efficacy of intravesical gemcitabine/docetaxel in high-risk non-muscle-invasive bladder cancerPietro Scilipoti, Paolo Zaurito, Mattia Longoni, et al.
Annals of Surgical Oncology|March 21, 2026
Bladder Tumor Location Matters: Trigone and Bladder Neck Involvement Predict Worse Oncological Outcomes in High-Grade Non-Muscle-Invasive Bladder CancerAleksander Ślusarczyk, Marco Moschini, Wojciech Krajewski, et al.
Urologic Oncology|February 26, 2022
Variant histologies in bladder cancer: Does the centre have an impact in detection accuracy?Alessia Cimadamore, Chiara Lonati, Ettore Di Trapani, et al.
Pageof 14